Imbruvica generic
Imbruvica, an oral drug containing the active ingredient ibrutinib, is owned by Pharmacyclics Inc. This drug was first authorized for market use on 13 November 2013.
When will Imbruvica generic be available?
Imbruvica has a wide patent portfolio with about 80 patents owned. Focusing on the last patent, it is expected that the generic version of Imbruvica can potentially be released after 03 September 2036.
Imbruvica uses
Imbruvica is extensively used for the treatment of various forms of lymphoma and leukemia. Key treatments include relapsed or refractory small lymphocytic lymphoma; chronic lymphocytic leukemia; waldenstrom's macroglobulinemia; mantle cell lymphoma; marginal zone lymphoma; chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy. The active ingredient, ibrutinib, plays a crucial role in these treatments.
Imbruvica patent expiration
Imbruvica's patent details outline a broad range of patents with the earlier ones expiring around end of 2026 to the last ones in 2036. Notably, the last patent protects the pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor which expires on 03 September 2036. Consequently, the Imbruvica generic release could occur post this date. Below are the details of the patent: